Medicare does not typically cover ketamine infusions for mental health conditions. However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

“It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market ...

Months after Massachusetts voters rejected a ballot question that would permit adults to use and grow certain psychedelic drugs, some state lawmakers have begun proposing bills to legalize psilocybin.

Research also suggests that esketamine nasal spray doesn’t affect thinking skills the way high doses of ketamine do. What’s Next Along with treatment-resistant depression, Spravato is approved ...

The US FDA has approved the first of its kind ketamine-based nasal spray which ... the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ... behind them that the treatments work,” Merrill said. “Ketamine is a safe medication when used under appropriate professional ...

They also note that the oral tablets would be less prone to abuse and diversion than other ketamine formulations. They could also be cheaper, given that Spravato's US list price in the US is $590 ...